



# Biomarker-driven Alzheimer's therapy development solutions

From discovery to clinical trial support and diagnostic commercialization, Labcorp offers a broad array of important Alzheimer's biomarker options. Combined with our global clinical trial testing solutions, neurology-focused scientific expertise and flexible commercialization services; we can support your breakthrough more rapidly reaching patients in need.

## One partner to help you achieve your next Alzheimer's advancement

Collaborating with Labcorp means industry-leading laboratory services and solutions to help you discover, develop and deliver life-changing therapies that address neurodegenerative disorders, such as Alzheimer's.



### Proven Experience

Leverage Labcorp's deep knowledge supporting 90+ Alzheimer's disease protocols—in 45+ countries with 96,000+ patients—in the last 5 years alone



### Global Reach

Experience holistic clinical trial testing delivered by a global laboratory network with critical sample management and logistics capabilities



### Therapeutic Area and Scientific Expertise

Gain comprehensive and specialized neurology expertise for support from strategy to lab with our Biomarker Solution Center and global translational biomarker scientists



### Data-Driven Insights

Optimize your neurodegenerative biomarker-driven development with unparalleled data to support trial design, site selection and patient enrollment



### Flexible Commercialization Solutions

Have your Alzheimer's therapy available to patients on day one with customized services from companion diagnostic development to sponsored testing

## An extensive biomarker portfolio to drive your global development\*

Access Labcorp's expansive menu of Alzheimer's tests to support your clinical trial testing needs.

Category	Analyte	Sample Type	Platform	Region
<b>A</b>	Amyloid Beta 42/40	CSF	Fujirebio® Lumipulse	US
	Amyloid Beta 42/40	EDTA Plasma	Sysmex	US
	Amyloid beta (1-40)	CSF	Fujirebio Lumipulse® CLEIA	US, EU, APAC
	Amyloid beta (1-40)	EDTA Plasma	Sysmex HISCL	US
	Amyloid beta (1-40)	EDTA Plasma	Fujirebio Lumipulse® CLEIA	EU
	Amyloid beta (1-42)	CSF	Fujirebio Lumipulse® CLEIA	US, EU, APAC
	Amyloid beta (1-42)	EDTA Plasma	Fujirebio Lumipulse® CLEIA	EU
	Amyloid beta (1-42)	EDTA Plasma	Sysmex HISCL	US
	Amyloid beta (1-42)	CSF	Roche cobas®	EU
<b>T</b>	pTau181	EDTA Plasma	Roche cobas®	US
	pTau181	EDTA Plasma	Fujirebio Lumipulse® CLEIA	US, EU
	pTau181	CSF	Fujirebio Lumipulse® CLEIA	US, EU, APAC
	pTau181	EDTA Plasma	Quanterix SIMOA®	US
	pTau217	EDTA Plasma	Fujirebio Lumipulse®	US, EU
	pTau217	EDTA Plasma	Quanterix SIMOA®	US
	Total Tau	CSF	Fujirebio Lumipulse® CLEIA	US, EU, APAC
	Total Tau	CSF	Roche cobas®	EU
	Total Tau	CSF, EDTA Plasma	Quanterix SIMOA®	US
	Total Tau	CSF	Fujirebio Lumipulse® CLEIA	US, EU, APAC
<b>N</b>	NfL	Serum, EDTA Plasma	Roche cobas®	US
	NfL	Serum, EDTA Plasma	Quanterix SIMOA®	US, EU
<b>Other</b>	GFAP	EDTA Plasma	Roche cobas®	US
	GFAP	CSF, Plasma	Quanterix SIMOA®	US
	Multi: Amyloid Beta 1-42, 1-40, NfL, GFAP (Neuro 4-plex)	EDTA Plasma	Quanterix SIMOA®	US
	Multi: Amyloid Beta 1-42, 1-40, T-tau	CSF, Plasma	Quanterix SIMOA®	US
	Multi: Amyloid Beta 42, pTau181, t-tau	CSF	Roche cobas®	US
	Heat Shock Protein 70 (HSP70)	CSF	Quanterix SIMOA®	US
	Alz Bio3 Panel: Beta Amyloid 1-42, Tau, Tau [Phosphorylated (p181)]	CSF	Innogenetics/Luminex®	US
	CHI3L1 (YKL-40)	CSF, EDTA Plasma	Enzyme Immunoassay	US, EU, APAC
	APOE Genotyping (rs429358, rs7412)	EDTA Whole Blood, Buccal Swab	ThermoFisher Scientific TAQMAN/ABI QuantStudio	US, EU, APAC

\*As of March 2024. Please contact us for the latest test availability.

### Contact Us

Let's discuss your program and determine how we can help you accelerate your Alzheimer's innovation and bring the power of precision medicine to more patients.

Visit [labcorp.com/neurology/neurodegenerative-diseases/pharmaceutical-partners](https://labcorp.com/neurology/neurodegenerative-diseases/pharmaceutical-partners) for additional information about our global research solutions for neurodegenerative disease.

